TKM Share Price

Open 22.42 Change Price %
High 23.42 1 Day 0.52 2.32
Low 21.56 1 Week 0.00 0.00
Close 22.97 1 Month 0.00 0.00
Volume 124457 1 Year 0.00 0.00
52 Week High 50.45
52 Week Low 36.19
TKM Important Levels
Resistance 2 24.69
Resistance 1 23.98
Pivot 22.65
Support 1 21.96
Support 2 21.25
TSE Canada Most Active Stocks
BIN 41.40 -1.62%
BIN 41.40 -1.62%
LSG 2.08 8.33%
LSG 2.08 8.33%
LSG 2.08 8.33%
TBE 0.03 0.00%
BBD-B 2.33 3.56%
SVC 3.86 22.54%
SVC 3.86 22.54%
SVC 3.86 22.54%
More..
TSE Canada Top Gainers Stocks
TVI 0.02 100.00%
CUR 0.02 100.00%
CUR 0.02 100.00%
CUR 0.02 100.00%
PWC 0.10 25.00%
PWC 0.10 25.00%
SVC 3.86 22.54%
SVC 3.86 22.54%
SVC 3.86 22.54%
CUM 0.90 13.92%
More..
TSE Canada Top Losers Stocks
GBV 0.46 -24.59%
AAB 0.12 -14.29%
AAB 0.12 -14.29%
CTU-A 0.19 -9.52%
BKX 0.20 -9.09%
ONC 0.57 -8.06%
ONC 0.57 -8.06%
NCU 0.52 -7.14%
NCU 0.52 -7.14%
DEJ 0.14 -6.67%
More..

Tekmira Pharmaceuticals Corp (TSE: TKM)

TKM Technical Analysis 1.5
As on 3rd Mar 2015 TKM Share Price closed @ 22.97 and we RECOMMEND Buy for LONG-TERM with Stoploss of 19.30 & Sell for SHORT-TERM with Stoploss of 24.08 we also expect STOCK to react on Following IMPORTANT LEVELS.
TKM Target for May
1st Target up-side N/A
2nd Target up-side N/A
3rd Target up-side N/A
1st Target down-side N/A
2nd Target down-side N/A
3rd Target down-side N/A
TKM Other Details
Segment EQ
Market Capital 0.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.tekmirapharm.com
TKM Address
TKM
100-8900 Glenlyon Parkway
Burnaby, BC V5J 5J8
Canada
Phone: 604-419-3200
Fax: 604-419-3201
TKM Latest News
Arbutus Biopharma Corp (ABUS) Receives Daily Coverage Optimism Rating of 0.32   Sports Perspectives   - 29th May 17
Analysts Set Arbutus Biopharma Corp (ABUS) Price Target at $8.00   The Cerbat Gem   - 20th May 17
Arbutus Biopharma: 2 Ways For Shareholders To Win   Seeking Alpha   - 05th Apr 17
Arbutus Biopharma's (ABUS) CEO Mark Murray on Full Year 2016 Results ...   Seeking Alpha   - 22nd Mar 17
Arbutus Biopharma and Alexion in new licensing deal   Seeking Alpha   - 17th Mar 17
Arbutus Biopharma Corporation Is Poised To Catch Up In The Hepatitis B Race   Seeking Alpha   - 18th Nov 16
Arbutus Biopharma Is Currently In Second Place In The Race For An HBV Cure   Seeking Alpha   - 14th Jan 16
News Arbutus Biopharma Corp.ABUS   Wall Street Journal   - 07th Aug 15
Tekmira Announces Launch of Arbutus Biopharma, a Hepatitis B Solutions Company   GlobeNewswire (press release)   - 20th Jul 15
3.35   MarketWatch   - 29th Dec 13
Interactive Technical Analysis Chart Tekmira Pharmaceuticals Corp ( TKM TSE Canada )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Tekmira Pharmaceuticals Corp
TKM Business Profile
Tekmira Pharmaceuticals Corporation, a biopharmaceutical company, focuses on the research and development of RNA interference therapeutics; and provides lipid nanoparticle delivery technology to pharmaceutical partners in Canada. Its pipeline products include TKM-PLK1, an oncology product platform that is in Phase I/II clinical trials, which targets polo-like kinase 1, a protein involved in tumor cell proliferation and a validated oncology target; and TKM-HBV, which is in Phase I clinical trial to eliminate surface antigen expression in the chronically infected patients. The company is also involved in developing TKM-Ebola, an anti-ebola viral therapeutic that is in Phase I clinical trial; and TKM-Marburg to treat Marburg infections. In addition, its preclinical product candidate includes TKM-ALDH2 for the treatment of alcohol use disorder. The company has strategic alliances with Alnylam Pharmaceuticals, Inc.; Acuitas Therapeutics Inc.; Spectrum Pharmaceuticals, Inc.; Monsanto Company; Marina Biotech, Inc./Arcturus Therapeutics, Inc.; Merck & Co., Inc.; Bristol-Myers Squibb Company; and U.S. National Institutes of Health. Tekmira Pharmaceuticals Corporation is headquartered in Burnaby, Canada.